Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
NBIX Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
47.30%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
11.60%
NBIX Stock Analysis
NBIX
PE Ratio:
25.4
NBIX
PEG Ratio:
0.6
NBIX
Forward EPS Growth (12 month):
43.30%
NBIX
PS Ratio:
5.4
NBIX
PSG Ratio:
0.4
NBIX
Forward Revenue Growth (12 month):
14.80%
NBIX Articles
No data was found